Dr. Finn on New CDK 4/6 Inhibitors for Breast Cancer

Richard S. Finn, MD
Published Online: Monday, August 19, 2013
Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses new CDK 4/6 inhibitors for the treatment of breast cancer.

Other CDK inhibitors have been around a lot longer than palbociclib but have not broken out of the pack to show robust activity. Palbociclib, as a first-in-class CDK 4/6 inhibitor, has shown such benefit that there are now other CDK 4/6 inhibitors being developed.

These other drugs are in early phase and a ways behind, Finn says, so it remains to be seen how they can compete with palbociclib in the space.

Online CME Activities
Free CME from PER
31st Annual Miami Breast Cancer Conference® Clinical Vignette Series
Clinical Vignettes Series: Hematologic Malignancies
Miami Lung Cancer Conference™ Medical Crossfire®
Community Practice Connections: 18th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma
More Reading
Publications
$auto_registration$